This Company Anonymized 1.8 Trillion Records to Support Biomedical Research
There is a dillema: patient data privacy is a top priority, but patient data in the same time is crucial for advancing drug discovery and biomedical research by third party organizations. How to solve that?
The topic of biomedical data collection and processing received a lot of attention during @HLTHEurope 2024 taking place these days in Amsterdam, and one company that stood out to me in this field was Datavant.
At the heart of Datavant's technology is tokenization, a process that converts sensitive data, known as Personally Identifiable Information (PII), into a non-sensitive equivalent called a token.
This involves hashing and encrypting PII, transforming it into a token that cannot be reverse-engineered to reveal the original data.
For example, a name like "John Smith" is always converted into the same unique token.
Since different data sets may capture various PII elements, Datavant creates multiple tokens for a single piece of PII, ensuring comprehensive protection across diverse data environments.
Advanced algorithms enable these tokens to be matched across different records without exposing the underlying PII, allowing for the secure linkage of patient records from disparate sources.
Read my first-hand coverage of what Datavant is doing directly from HLTH Europe, where I am now reporting for BioPharmaTrend.com, the official media partner to the event.
#bigdata #lifesciences #healthcare
In the image: Devin Gilliam presenting about Datavant capabilities
M.Sc in Biological Sciences | Teaching, Research, Lab Management Expert
2wCongratulations